Early intervention with second-generation antipsychotics in first-episode psychosis: Results of an 8-week naturalistic study

Early Intervention in Psychiatry

Volumn 4, Issue 1, 2010, Pages 57-63

  Josiassen, Richard C ^a,b   Shaughnessy, Rita A ^a,b   Filymer, Dawn M ^b,c   Donohue, Ann Marie ^d   Kacso, Margit ^b,h   Finkel, Naomi ^e   Curtis, Jessica ^b,d   Audino, Brett ^b,f   Skuban, Nina ^g  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Translational Neuroscience LLC   (United States)

^c KUTZTOWN UNIVERSITY   (United States)

^d Montgomery County Community College   (United States)

^e Montgomery County Emergency Services   (United States)

^f UNIVERSITY OF THE SCIENCES   (United States)

^g Worldwide Clinical Trials   (United States)

^h CAPELLA UNIVERSITY   (United States)

Author keywords

EPS; First episode psychosis; Second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EARLY INTERVENTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATURALISTIC INQUIRY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; TIME FACTORS;

EID: 75649152091     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2010.00163.x     Document Type: Article

References (22)

1. May PR, Tuma AH, Dixon WJ. Schizophrenia: a follow-up study of the results of five forms of treatment. Arch Gen Psychiatry 1981, 38:776-84.
2. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull 1999, 25:721-9.
3. Sanger TM, Lieberman JA, Tohen M. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999, 156:79-87.
4. Malla AK, Norman RM, Scholten DJ. A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry 2001, 62:179-84.
5. Lieberman JA, Tollefson G, Tohen M. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003, 160:1396-404.
6. Schooler N, Rabinowitz J, Davidson M. Risperidone and haloperidol in first episode psychosis: a long-term randomized trial. Am J Psychiatry 2005, 162:947-53.
7. Robinson DG, Woerner MG, Napolitano B. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 2006, 163:2096-102.
8. Lieberman JA, Philips M, Gu H. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003, 28:995-1003.
9. McEvoy JP, Perkins DO, Gu H. Clinical effectiveness and predictors of treatment non-adherence: comparison of olanzapine, quetiapine, and risperidone in first episode psychosis. Am J Psychiatry 2007, 164:1050-60.
10. Sheitman BB, Lee H, Strauss R. The evaluation and treatment of first-episode psychosis. Schizophr Bull 1997, 23:653-61.
11. Robinson DG, Woerner MG, Alvir JMJ. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999, 156:544-9.
12. Robinson DG, Woerner MG, Delman H. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005, 31:705-22.
13. Kahn RS, Fleischacker WW, Boter H. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008, 371:1085-97.
14. Robinson DG, Woerner MG, Alvir JM. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002, 57:209-19.
15. Elbogen EB, Swanson JW, Swartz MS. Medication nonadherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability. J Nerv Ment Dis 2005, 193:673-67.
16. Addington J. The promise of early intervention. Early Interv Psychiatry 2007, 1:294-307.
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-76.
18. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
19. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-6.
20. Haas M, Eerdekens M, Kushner S. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009, 194:158-64.
21. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 2004, 24:429-36.
22. Mortensen PB, Juel K. Mortality and the causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993, 163:183-9.